Kornimate/medical-research-clean huggingface dataset:
preoperative application of chlorhexidine to reduce infection with cesarean section after labor

Conditions: Cesarean Section; Surgical Site Infection; Nosocomial Infection

Summary: surgical site infections (ssi) are the second most common cause of nosocomial infections accounting for 15% of all nosocomial infections among hospitalized patients and 38% of nosocomial infections in surgical patients. in obstetric patients, infectious morbidity (i.e. ssi, endometritis) occurs in 5-10% of cesarean sections, which is 5-fold higher than vaginal deliveries. additionally, infectious morbidity is thought to be highest in those patients who have cesarean sections after undergoing labor. chlorhexidine, a chemical antiseptic effective on gram positive and gram negative bacteria, reduces skin microflora/colonization but it is not clear if it decreases the risk of ssi. historically, chlorhexidine has been studied and used in orthopedic and cardiac implant surgeries. research on the use of chlorhexidine for ssi prevention in cesarean sections is limited. this study intends to evaluate the effectiveness of use of both chlorhexidine gluconate (chg) wipe and vaginal scrub in reducing ssi in patients undergoing cesarean section that have previously been laboring. patients will be randomized to one of two groups: wash with both a pre-operative chg cloth prior to surgery and chlorhexidine gluconate vaginal scrub in addition to standard preoperative scrub as compared to standard preoperative scrub alone.

the study will be offered to women who are admitted to undergo labor at mount sinai medical center. the eligible women will be randomized to use of a 2% chlorhexidine gluconate (chg) cloth with 4% chlorhexidine gluconate vaginal scrub (including standard preoperative care prior to cesarean section) or standard preoperative care. participants will not be blinded to the arm in which they have been assigned. researchers will have access to all patients scheduled for delivery at mount sinai medical center. about 1800 deliveries by cesarean section occur each year at mount sinai. of these, approximately 800 are cesarean sections after failed labor. assuming a primary outcome rate of 20% in the control arm, a sample size of 329 in each group would give 80% power to detect a 40% reduction in surgical site infection between the active group and control. the aim is to recruit 400 patients per group (for a total of 800 patients) to account for patient drop out or non-compliance. sage products, inc will be providing the chg cloths. this study intends to show that simultaneous use of 2% chg cloths and 4% chg vaginal scrub prior to cesarean section will reduce the rate of ssi in women who have previously been laboring.

Eligibility criteria:
inclusion criteria: * women at \> 24 weeks gestation who are admitted in labor or admitted for induction of labor at mount sinai hospital exclusion criteria: * allergy to chlorhexidine * unplanned or emergency cesarean section * women at \<24 weeks gestation * estimated fetal weight \<500 grams * fetal face presentation regardless of gestational age.

Keywords: cesarean section labor surgical site infections chlorhexidine gluconate
circulating tumour cells in patients with peritoneal metastases

Conditions: Circulating Tumor Cell; Peritoneal Metastases; Hyperthermic Intraperitoneal Chemotherapy

Summary: this study aims to evaluate the prognostic value of circulating tumour cells (ctc) in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due to gastrointestinal cancers that have spread to the peritoneum.

ctcs har extracted by way of a new method at baseline, during surgery, and postoperatively. the occurence of such ctcs will be investigated for prognostic evaluation. patients will be follow-up by clinical routine. disease recurrence and overall survival will be the endpoint used.

Eligibility criteria:
inclusion criteria: * peritoneal metastases being treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy exclusion criteria: * none
a phase 1b study evaluating gs-9820 in subjects with lymphoid malignancies

Conditions: Lymphoid Malignancies

Summary: this study is to determine the appropriate dosing regimen of gs-9820 in subjects with lymphoid malignancies. this is a phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of gs-9820.


Eligibility criteria:
inclusion criteria: * previously treated recurrent b-cell inhl, dlbcl, mcl, hl or cll * measurable lymphadenopathy * requires therapy exclusion criteria: * recent history of a major non-lymphoid malignancy * evidence of ongoing infection * concurrent participation in another therapeutic clinical trial

Keywords: chronic lymphocytic leukemia (cll) non-hodgkin lymphoma (nhl) hodgkin lymphoma (hl) indolent non-hodgkin lymphoma (inhl) diffuse large b-cell lymphoma-activated b-cell (dlbcl-abc) dlbcl-germinal center b-cell (gcb) mantle cell lymphoma (mcl) gs-9820 phosphatidylinositol 3-kinase (pi3k)
chidamide plus r-chop in elderly dlbcl

Conditions: Diffuse Large B-cell Lymphoma

Summary: this is a prospective, single-arm, open-label phase ii study of chidamide in combination with r-chop in the treatment of de novo, elderly, high-risk diffuse large b cell lymphoma patients.


Eligibility criteria:
inclusion criteria: * pathologically confirmed diffuse large b-cell lymphoma, cd20 positive * age 61-75 years * ecog 0,1,2 * life expectancy\>6 months * informed consented * ipi\>1 exclusion criteria: * chemotherapy before * stem cell transplantation before * history of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease * primary cns lymphoma * lvef≤50% * lab at enrollment (unless caused by lymphoma) neutrophile\ 2\*uln,akp or bilirubin \>1.5\*uln creatinine\>1.5\*uln * other uncontrollable medical condition that may that may interfere the participation of the study * not able to comply to the protocol for mental or other unknown reasons * pregnant or lactation * hiv infection * if hbsag positive, should check hbv dna, dna positive patients cannot be enrolled. if hbsag negative but hbcab positive (whatever hbsab status), should check hbv dna,dna positive patients cannot be enrolled.
hcv, hbv, hiv testing during consultation with anesthesiologist

Conditions: HCV; HBV; Hiv

Summary: the aim of the study is to assess the feasibility of hcv, hbv, hiv testing (according to the national guidelines) during consultation with anesthesiologist before a planned surgery in lariboisiere hospital, paris, france. the feasibility will be the number of tested patients divided by the number of patients who should have been tested according to the national guidelines (for each virus).

the aim of the study is to assess the feasibility of hcv, hbv, hiv testing during consultation with anesthesiologist before a planned surgery in lariboisiere hospital, paris, france. the national guidelines recommend at least one hiv testing during life and, more recently, one hcv testing during life to eradicate hcv infection. hbv testing is recommended in patients coming from high prevalence countries, ivdu, prisoners, patients with multiple sexual partners. the feasibility will be the number of tested patients divided by the number of patients who should have been tested according to the national guidelines (for each virus). hiv testing will use finger-stick whole blood (fsb) insti® hiv-1 \& hiv-2 rapid antibody test fsb (biolytical tm laboratories inc., richmond, b.c., canada), with a sensitivity 99% \[96.3-99.7\] and a specificity 99.3%. hcv testing will use finger-stick whole blood (fsb) oraquick® hcv test, with a sensitivity and a specificity 99.1 and 100% respectively. hbv testing will use finger-stick whole blood (fsb) vikia® hbs ag test, biomérieux with a sensitivity and a specificity 96.5 and 99.9% respectively.

Eligibility criteria:
inclusion criteria: * patient ≥ 18 years-old * planned surgery in lariboisiere hospital, paris, france * able to give written informed consent for testing * proposed to be tested for hiv and hcv if no previous testing found in the medical record * proposed to be tested for hbv if the patient belong to a high-risk group: high prevalence area (asia, sub-saharan africa, french indies, east and south europe, north-africa, middle-east, india, pakistan, south-america), ivdu, prisoners, unprotected sexual intercourses. exclusion criteria: * patient \< 18 years-old * emergency surgery * unable to give written informed consent for testing: psychiatric diseases, neurologic diseases, ... * a previous testing for hiv and hcv found in the medical record and no obvious risk factor after previous testing * the patient does not belong to a high-risk group for hbv
biomarker profiling in abdominal aortic aneurysm patients

Conditions: Abdominal Aortic Aneurysm

Summary: the biomarcs-aaa study aims to investigate the associations of (temporal patterns of) blood biomarkers with aneurysm growth in patients with abdominal aortic aneurysm (aaa), with particular attention to biomarkers that have demonstrated prognostic value for adverse disease outcomes in coronary artery disease and biomarkers for the main genetic pathways associated with aaa.

biomarcs-aaa is an observational, multicenter study. patients with an abdominal aortic aneurysm (aaa) will be recruited through the vascular surgery outpatient clinic of erasmus mc and maasstad ziekenhuis, the netherlands. the prospective, longitudinal part of the study will include an arm with 120 aaa watchful waiting patients and an arm with 120 aaa patients undergoing endovascular aneurysm repair (evar), both with a 24-month follow-up period. clinical data collection, and blood sampling will be conducted at baseline, at 1 month after evar and at 6, 12, 18 and 24 months for all patients. ct will be conducted at baseline and 12 and 24 months, plus at 1 month in the evar patients. quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients, and at 1 month only in evar patients. additionally, a cross-sectional study will be performed in 200 patients treated for aaa with evar in the past years. in these patients, clinical data collection, blood sampling, ultrasound and ct will be performed at their next regular outpatient clinic visit.

Eligibility criteria:
inclusion criteria: * age of 18 years or older * capable of understanding and signing informed consent and one of the following 1. diagnosis of aaa, with a diameter ≥40mm, based on any imaging technique and treated by watchful waiting strategy (prospective longitudinal study, arm 1 watchful waiting group) 2. planned to undergo evar for aaa (prospective longitudinal study, arm 2 evar group) 3. underwent evar for aaa in past years (cross-sectional study) exclusion criteria: * patients with isolated iliac artery aneurysm, traumatic aneurysm, anastomotic aneurysm and infectious aneurysm * patients with a clinical diagnosed thoracic aneurysm (i.e. located in the chest, above the diaphragm) * coexistent condition with life expectancy ≤ 1 year * dialysis dependent, (end stage) renal disease patients * women of childbearing age * linguistic barrier * unlikely to appear at all scheduled follow-up visits

Keywords: abdominal aortic aneurysm biomarkers
urinary incontinence and transtheoretical model

Conditions: Urinary Incontinence

Summary: the aim of the study is to evaluate the effectiveness of nursing care given online to women with urinary incontinence based on the transtheoretical (change) model.

the research was planned as a randomized experimental design with pre-test and post-test control groups. the research will be conducted in kutahya, turkey. a total of seven online interviews will be conducted with the women in the experimental group, one of which is pre-test, one is the last interview where the post-tests are applied, and five of which are motivational. women in the experimental group were interviewed every 2 weeks and the women will be followed up by phone/mail every 2 weeks. a total of two online interviews will be conducted with women in the control group, one of which is a pre-test interview and one is a final interview where post-tests are applied. no application will be made to women in the control group. all online calls to be made will be conducted via the whatsapp application.

Eligibility criteria:
inclusion criteria * 18 years or above * diagnosis of urinary incontinence according to the international consultation of incontinence questionnaire - short form (iciq-sf) * mild to moderate incontinence according to the incontinence severity index (isi) * having a smartphone * using the whatsapp application * being at one of the stages of pre-contemplation, contemplation, preparation, and action according to the evaluation form for stages of change * volunteering to participate in the study exclusion criteria * having risk factors that are thought to affect urinary incontinence (pregnancy; giving birth within the last year; having been diagnosed with recurrent urinary tract infection; having any health problem affecting the muscle and/or nervous system; having been diagnosed with a disease that increases intra-abdominal pressure and causes coughing, such as asthma, chronic obstructive pulmonary disease; using drugs that may cause urinary incontinence, such as diuretics, anticholinergics, antidepressants, antiparkinsonian, antihistamines, sedatives, narcotic analgesics for the past year; having been diagnosed with pelvic organ prolapse; receiving education and treatment for urinary incontinence in the last year) * being at the maintenance stage according to the evaluation form for stages of change * not volunteering to participate in the study

Keywords: urinary incontinence transtheoretical model motivational interviewing nursing care
a study of danoprevir boosted with low dose ritonavir in combination with pegasys and copegus in treatment-naive patients with chronic hepatitis c virus infection

Conditions: Hepatitis C, Chronic

Summary: this randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with pegasys (peginterferon alfa-2a) and copegus versus pegasys and copegus alone in treatment-naive patients with chronic hepatitis c.


Eligibility criteria:
inclusion criteria: * adults patients, \>/=18 years of age * chronic hepatitis c, genotype 1 and 4 * hcv rna \>/=50,000 iu/ml * treatment-naive exclusion criteria: * patients with cirrhosis or incomplete/transition to cirrhosis * patients with other forms of liver disease, hiv infection, hepatocellular carcinoma or severe cardiac disease
effectiveness of stabilization exercise in youth basketball players with ankle sprain

Conditions: Basketball Player; Injury, Ankle

Summary: ankle injuries are one of the most common sports injuries. ankle injuries account for 10% to 30% of all injuries and 5% to 20% of all time-wasting injuries. athletes involved in sports such as football, basketball, and volleyball are particularly at risk for such injuries, largely due to the running and jumping activities involved. basketball has one of the highest injury rates of any team sport, with 10 injuries in a 1000 hour period.

the ankle is anatomically strong because of the structure of the bones and ligature that make it. despite this, ankle injuries are the most common type of injury in sports injuries due to the stress and impact of athletes. it is estimated that 25% of the injuries occurred were ankle injuries. approximately 85% of ankle injuries are lateral ankle sprain. in basketball, ankle sprain is the most common type of injury. this is because repeated jumps, landings and sudden changes of direction in the nature of basketball. due to degeneration in the bond structure as a result of ankle sprained, balance problems are also seen in athletes. therefore, it is important that athletes evaluate the jump performance. in order to better understand the type and severity of injury of athletes, it is necessary to assess not only the physical characteristics but also the anxiety of physical activity and the relationship between this anxiety and injury, as fear of moving in athletes can develop as physical and psychological maturity is not developed enough during the pub period. the fear of moving can negatively affect the healing phases of the injured athlete, or even delay healing. plyometric training has been proven to improve muscle strength and power production. in addition, regular exercise can lead to significant improvements in postural control, jumping, sprinting, diversion speed and agility performance in young basketball players. fear of re-injury is the fear of being vulnerable to painful re-injury even though physical recovery has been achieved. this situation also has an effect on psychological changes such as movements to protect the muscles, insecurity and focusing problems in the physiologically injured area. studies show that fear of re-injury also influences muscle activation patterns, influencing muscle recovery, neuromuscular function, and rehabilitation outcomes. as a result, this delays the return to sports.

Eligibility criteria:
inclusion criteria: between 14-18 years old become a licensed male basketball player playing in the istanbul league of the turkish basketball federation 5 days a week, more than 1.5 hours a day to train exclusion criteria: played a match in the 48 hours before the assessment no lower extremity injury other than ankle

Keywords: exercise basketball player jump kinesiophobia
new treatment for nocturnal enuresis in children

Conditions: Nocturnal Enuresis in Children

Summary: the aim of the study is to evaluate the role of sulbutiamine in treatment of monosymptomatic nocturnal enuresis in children by using it alone or as a combination therapy with tricyclic antidepressants (imipramine+sulbutiamine).


Eligibility criteria:
inclusion criteria: * age : 6 - 18 years old. * all children diagnosed by primary monosymptomatic nocturnal enuresis in this age group. exclusion criteria: * secondary nocturnal enuresis (child who has been continent for at least 6 months before the onset of bedwetting ). * congenital anomalies (posterior urethral valve , ectopic ureter , ectopia vesica ,...) * history of previous lower urinary tract surgery (multiple hypospadias surgeries ,..., ) * neurogenic bladder (as underactive bladder ).and urge incontinence. * presence of post-void residual urine greater than 20% of functional bladder capacity. * history or evidence of disorders in other organs such as (cardiovascular system disease), liver , psychological problems , evident allergic reaction to both medication.

Keywords: treatment of monosymptomatic nocturnal enuresis in children using sulbutiamine
role of vitamin d and its topical analogues in pathogenesis and treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: acne vulgaris is a chronic skin disease of the pilosebaceous unit characterized by formation of papules, pustules, comedones, nodules and cysts. it can have a major psychological burden on the patients. it develops due to blockage of the hair follicles. this is thought to occur as a result of the following four abnormal processes: a higher than normal amount of sebum production, excessive deposition of keratin leading to comedo formation, hair follicles' colonization by propionibacterium acnes (p. acnes) and the local release of pro-inflammatory mediators. androgens also play a role in pathogenesis either from elevated levels or exacerbated response

in 2015, acne was estimated to affect 633 million people globally, making it the 8th most common disease worldwide. acne commonly occurs in adolescence and affects an estimated 80-90% of teenagers. children and adults may also be affected before and after puberty many treatment options for acne are available, including lifestyle changes; such as eating healthy, medications (topical and systemic) and medical procedure.despite of the availability of many therapeutic modalities, none of them has proved to be ideal. recently, vitamin d was proved to be an exciting option for treating many chronic inflammatory dermatological diseases. it appears to have systemic antimicrobial and other effects that may be crucial in a variety of both acute and chronic illnesses. vitamin d regulates the immune system, furthermore, it has antioxidant and anti-comedogenic properties. so, vitamin d deficiency maybe involved in the pathogenesis of acne vulgaris . thus,vitamin d use could potentially reduce inappropriate antibiotic prescription and boost therapeutic response, either as a monotherapy or in combination with other anti-acne medications. high glycemic food intake and excessive consumption of dairy products as well as of saturated fatty acids were all suggested to have an influence on av course. in addition, obesity has been reported to be associated with acne. interestingly, genetic studies found out that obesity can drive down vitamin d levels so, there seems to be a theoretical background about the association between acne vulgaris, vitamin d and obesity

Eligibility criteria:
inclusion criteria: 1. patients with acne of any grade. 2. patients between 18 and 45 years old. exclusion criteria: 1. patients below 18 and above 45years. 2. patients with any concomitant dermatologic or systemic illness 3. patients on any topical or systemic medication within 4 weeks before enrollment. 4. pregnancy.
efficacy and safety of pt001 to placebo and open-label spiriva® respimat® in subjects with persistant asthma

Conditions: Asthma

Summary: study comparing the efficacy and safety of pt001 to placebo and open-label spiriva® respimat® in subjects with persistent asthma

a randomized, double-blind, parallel group, multi-center 24-week study comparing the efficacy and safety of three doses of pt001 to placebo and open-label spiriva® respimat® in subjects with persistent asthma

Eligibility criteria:
inclusion criteria: * have a documented history of physician-diagnosed asthma * require inhaled asthma maintenance therapy: has been regularly using an ics/laba on a stable regimen for at least 4 weeks * documented reversibility to albuterol * a pre-bronchodilator fev1 \>40% and \ 40% and \<90% of predicted for subjects 12 to \<18 years of age * demonstrate acceptable spirometry performance * willing and, in the opinion of the investigator, able to adjust current asthma therapy, as required by the protocol * compliance: must be willing to remain at the study center as required per protocol to complete all visit assessments exclusion criteria: * oral corticosteroid use (any dose) within 4 weeks * current smokers, former smokers with \>10 pack-years history, or former smokers who stopped smoking \<6 months (including all forms of tobacco, e-cigarettes, and marijuana) * life-threatening asthma as defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s) * completed treatment for lower respiratory infection or asthma exacerbation within 4 weeks * hospitalizations for asthma within 3 months * historical or current evidence of a clinically significant disease * cancer not in complete remission for at least 5 years * treatment with investigational study drug (or device) in another clinical study within the last 30 days or 5 half-lives, whichever is longer * previously randomized in any pt001 study